Numerous studies identified STING as a promising target for cancer immunotherapy [7–11] and modified synthetic STING agonists are currently tested in clinical setting, mostly in combination with anti-programmed death 1 (PD-1) antibodies [12]. The gene discussed is STING1; the disease is cancer.